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Scout Treadwell: The Effects of Alpha-Tocopherol and Ascorbic Acid on Metastatic 
Breast Cancer Cells  
 Breast cancer is a multifaceted, complex disease that affects hundreds of 
thousands of patients every year. Although there has a been a decline in the mortality rate 
of this disease, it is still vital to investigate and discover new possible treatments. One 
area of research involves the generation of reactive oxygen species (ROS) in cancer cells 
and the possibility of ROS-induced apoptosis. Antioxidants such as Vitamin C and 
Vitamin E have been shown to serve as pro-oxidants. Instead of detoxifying the cell from 
damaging ROS, these compounds can stimulate ROS production, triggering an apoptotic 
cascade in the cell. In this study, Vitamin C and Vitamin E at varying concentrations 
were applied to four different cell lines, MCF-7, BOM-1883, MDA-MB-231, and MCF-
7-BOM. After the cells were treated, an SRB assay was performed in order to determine 
the cell viability. The effects of hypoxia (low oxygen tension) on cancer cells was also 
studied in this research. The results showed that MCF-7 cells were most susceptible to 
Vitamin C treatment. Findings also showed that a hypoxic environment deceased cell 
proliferation relative to normoxic control. The effects of Vitamin E were insignificant, 
which is consistent with researched literature. However, the findings for Vitamin C were 
of more interest because there have been several studies that have shown the positive 







TABLE OF CONTENTS  
 
 
List of Figures……………………………………………………………...VI 
List of Tables………………………………………………………………VII 
List of Abbreviations………………………………………………………VIII 
Introduction 
 Cancer…………………………………………………………….....1 
 Breast Cancer……………………………………………………......5 
 Breast Cancer Staging…………………………………………….....7  
 Importance of Research…………………………………………......12 
 Natural Products…………………………………………………….13 
 Cancer and Mitochondrial Respiration……………………………..14  
Materials and Methods 
 Cell Culture/ Compound Treatment..................................................18 















LIST OF FIGURES 
 
Figure 1: Hallmarks of Cancer......................................................................4 
Figure 2: In Situ Non-Invasive vs. Invasive Cells………………………….8 
Figure 3: Vitamin E Molecular Structure…………………………………13 
Figure 4: Vitamin C Molecular Structure…………………………………13 
Figure 5: Inhibition of Tumor Cell Proliferation by Vitamin C after 48 hours  
at Various Concentrations.............................................................................23 
Figure 6: Inhibition of Tumor Cell Proliferation by Vitamin E after 48 hours  
at Various Concentrations.............................................................................24 
Figure 7: Cell Proliferation/Viability after 48 hours under normoxic and  





















LIST OF TABLES 
Table 1: Vitamin C Dilutions..............................................................21 
Table 2: Vitamin E Dilutions..............................................................22 
Table 3: Vitamin C Concentrations in a 96-Well Plate.......................22 
Table 4: Vitamin E Concentrations in a 96-Well Plate.......................23 
Table 5: Vitamin C IC50 Values..........................................................28 


























LIST OF ABBREVIATIONS 
ATP   Adenosine Triphosphate 
BCL-2   B-Cell Lymphoma 2  
BRCA  1  Breast Cancer Gene 1 
BRCA 2   Breast Cancer Gene 2 
CTL   Cytotoxic T Lymphocytes 
DMSO   Dimethyl Sulfoxide 
DNA   Deoxyribonucleic Acid 
ECM   Extracellular Matrix 
EMT    Epithelial-Mesenchymal Transition 
ER   Estrogen Receptor 
ERK   Extracellular Regulated Kinase 
FDG   18F-glurodeoxyglucose 
GLUT1  Glucose Transporter 1 
GSH   Glutathione  
GSSG   Glutathione Disulfide  
HER2   Human Epidermal Growth 2 
HIF-1  Hypoxia-Inducible Factor-1alpha  
HT   Helper T  
IDC   Invasive Ductal Carcinoma 
IHC   Immunohistochemistry  
ILC   Invasive Lobular Carcinoma  
JNKs    Jun N-terminal kinases 
MAPK   Mitogen Activated Protein Kinase 
 IX 
MET    Mesenchymal-Epithelial Transition 
MRM   Modified Radical Mastectomies 
mRNA   Messenger Ribonucleic Acid  
NK   Natural Killer  
PBS   Phosphate Buffered Saline 
PET   Positron Emission Tomography  
PI3K   Phosphoinositide 3-kinase 
PM   Prophylactic Mastectomies 
PR   Progesterone Receptor 
ROS   Reactive Oxygen Species 
SH   Thiol Group  
SRB   Sulforhodamine B 
SSM   Skin-sparing mastectomies 
TCA   Trichloroacetic Acid 
TM   Total Mastectomies  
TME   Tumor Microenvironment  
TNM   Tumor, Node Metastasis 
UV   Ultraviolet 
VEGF               Vascular Endothelial Growth Factor 





 The human body is made of trillions of cells. Every day, these cells undergo 
replication and division in order to support the ever-changing needs of the body. 
Normally, there are checkpoints in the cell cycle to ensure controlled growth. However, 
multiple factors such as inherited genes or even environmental factors like tobacco, 
radiation, and ultraviolet (UV) rays break down this tightly regulated process because 
deoxyribonucleic acid (DNA) has been altered in some way. Because cancer is related to 
a change in DNA sequences, it can be considered a genetic disease. Once mutated, the 
cells can ultimately resist responses that signal apoptosis or halt cell division. Cancer 
cells are able to proliferate in response to their own signal, which causes rapid cell 
growth, cell survival, and increased cell metabolism (Hanahan, 2011).  
 Drs. Hanahan and Weinberg have proposed eight hallmarks that constitute the 
complexity of developed cancer. They include sustaining proliferative signaling, evading 
growth suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis, activating invasion and metastasis, dysregulating cellular energetics, and 
avoiding immune destruction. They have also noted two enabling characteristics of 
cancer. These characteristics include genome instability and mutation and tumor-
promoting inflammation (Hanahan, 2011).  Normally, proliferation is tightly controlled 
by specific growth factors that are secreted by certain cells that instruct the entry and 
progression through the cell growth-and-division cycle (Hanahan, 2011). This tightly 
regulated process ensures growth homeostasis in cells. However, one of the fundamental 
traits of cancer cells involves the ability to deregulate these growth signals and begin self-
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activated chronic proliferation. In the case of cancer, cells sustaining their own 
proliferation begin to secrete their own growth factors and can increase the number of 
growth factor receptors on the surface of the cell, which increases growth signal binding 
and proliferation. While ensuring constant proliferation, cancer cells must also 
circumvent signals that inhibit proliferation and growth. Tumor suppressor genes work to 
limit cell growth and manages whether or not the cell proceeds through the growth and 
division cycle. If deactivated, mutated tumor suppressor genes do not stop the 
proliferation of cells and continual growth is possible. Apoptosis, often known as cell 
death or cell suicide, serve as important regulator in cell balance. Apoptosis is a system 
designed to kill cells when there is a disruption in the cell cycle, a mistake in the DNA or 
if the cell has become old and damaged. Proteases, such as caspases 8 and 9, are activated 
by certain signals. This activation leads to a cascade of events that ultimately disrupts the 
integrity and disassembles the cells. Apoptosis remains a function of cells but there are 
certain abnormalities that decrease cells’ susceptibility to apoptotic signals. Methods 
cancer cells can use to limit apoptosis include the loss of tumor suppressor function and 
downregulation of proapoptotic signals. Cancer cells must be able to replicate themselves 
an infinite amount of times for tumor growth and metastasis. Replication immortality is 
achieved through the alteration of telomeres. Telomeres protect the end of chromosomes 
and can allow limited number of chromosomal replications. Telomeres shorten after each 
replication. However, telomerase is a specialized DNA enzyme that adds telomere 
repeats to the end of each chromosome. Through increased telomerase expression in 
cancer cells, cells can ultimately divide at infinite levels because the telomere length is 
never affected. In order for cancer cells to further survive, angiogenesis, the development 
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of new blood vessels, is necessary for tumor progression (Hildreth, 2009). New blood 
vessels can feed nutrients and oxygen into the growing tumors resulting in increased rates 
of growth and proliferation (Hildreth, 2009). Angiogenesis is stimulated by the secretion 
of Vascular Endothelial Growth Factor (VEGF). The secretion of VEGF is triggered by 
either hypoxia (oxygen depleted scenarios) or by oncogene signaling (Hanahan, 2011). 
The VEGF then binds to specific tyrosine kinase receptors known as Vascular 
Endothelial Growth Factor Receptors (VEGFR). Angiogenesis contributes to the 
microenvironment of cancer cells ensuring ample nutrition of growth, proliferation, and 
metastasis. Once cells begin the road of rapid, unwanted growth, tumors can form. In 
tumor cells, there is reprogramming of metabolism to support continuous cell growth 
(Hanahan, 2011).  These adjustments fuel further cell growth and division. In the 
dysregulating of cellular energetics, there is a metabolic switch from aerobic to anaerobic 
metabolism. This change calls for an up regulation in glucose transporters, like glucose 
transporter 1 (GLUT1), that increases the glucose importation to the cytoplasm. The 
increased glucose uptake can be visualized via positron emission tomography (PET) with 
a radio-labeled analog of glucose, 18F-glurodeoxyglucose, (FDG) as a reporter for the 
PET scan (Hanahan, 2011). Cancer cells are also able to avoid immune destruction. 
Typically, the immune system is triggered by certain antigens. The system is then capable 
of killing these irregular cellular formations. However, cancer cells resist the eradication 
from immune cells therefore limiting the extent of immunological killing. The immune 
system is typically suppressed in cancer cells resulting in deficiencies of cytotoxic T 
lymphocytes (CTLs), helper T (HT) cells, and natural killer (NK) cells (Hanahan, 2011). 
Because these components of the immune system are disabled, progressing tumor cells 
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are able to evade immune attack. Cancer progression increases the rate of mutation. With 
cancer cells, there is an increased sensitive to mutagenic agents. Typically, cells have 
surveillance systems that monitor the genome integrity, but this has been found to be 
compromised by cancer cells (Hanahan, 2011). Genes that detect DNA and genome 
damage are suppressed by tumor progression, very similar to the suppression of tumor 
suppressor genes. Tumor cells can also mirror inflammatory conditions. This 
inflammation can supply bioactive molecules, like growth factors, to the tumor 
microenvironment (TME) that sustain proliferation and signaling and also molecules that 
lead to the of epithelial-mesenchymal transition EMT. It has also been shown that 
inflammatory cells can release chemicals like ROS (Hanahan, 2011). 
 
Figure 1: Hallmarks of Cancer. Adapted from Hanahan and Weinberg 2011.  
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Once a tumor develops, it can either be classified as benign or malignant. Benign 
tumors are considered non-cancerous because they do not invade or spread into other 
tissues in the body. Contrastingly, malignant tumors are capable of spreading throughout 
the body. New tumors stemming from an original site is a result of this metastasis. Tumor 
cells metastasize moving through the circulatory or lymphatic system from tissue to 
tissue. Metastasis happens in a multistep process starting with local invasion and the 
climax of metastasis resulting in the escape of cancer cells from the lymphatic or 
circulatory system and the formation of small modules of cancer cells. Local invasion 
occurs when the cancer cells undergo EMT, travel through the body, then and attach to 
each other or healthy cells in the extracellular matrix (ECM) through a mesenchymal-
epithelial transition (MET) resulting in an increase in epithelial cadherin proteins and 
local cell to cell adhesion. The EMT process allows cancer cells to travel through the 
body and MET allows them to colonize again. Increasing growth in additional tissues is 
officially considered cancer colonization (Hanahan, 2011). Once detected and biopsied, a 
treatment plan can be created to ensure the best possible outcome for the patient. 
Depending on the type of cancer and the stage, the survival rate and treatment plan can 
look extremely different.  
BREAST CANCER 
 Breast cancer is considered the second most common form of cancer in women 
after skin cancer. In 2018, 252,710 women in the United States were diagnosed with 
Breast Cancer and over 40,000 of those diagnoses ended in death (“Breast Cancer 
Statistics and Resources”, 2019). While the mortality rate of cancer for breast cancer has 
decreased over the years, diagnosis is still very prevalent among women. This decrease in 
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mortality can be directly attributed to new treatments as well as early detection in women 
through mammograms. However, despite advances in medicine, it is still said that one in 
every eight women will be diagnosed with some form of breast cancer in their life 
(“Breast Cancer Risk in American Women”, 2012). Further research and coming to 
understanding the signs, symptoms, metabolism and metastasis of breast cancer is crucial 
to further decrease the prevalence of breast cancer in the United States. 
 Similar to all types of cancer, breast cancer is a tumor formed by uncontrolled cell 
growth and apoptosis. This specific malignancy begins in the breast tissue known as 
lobules which are the glands responsible for breast milk production (“Breast Cancer 
Statistics and Resources”, 2019). While the specific cause of breast cancer can be 
difficult to determine, there are multiple factors which can contribute to development. 
Inherited genes are considered to play an important role in determining a woman’s risk of 
being diagnosed with breast cancer. Accumulation of altered genes can result in the 
activation of a proto-oncogene to an oncogene or deactivation of tumor suppressor genes 
(Luo, 2001). Normally, proto-oncogenes are vital to the healthy growth of cells. Once 
mutated to oncogenes, cells begin to grow and divide at a dangerous rate (“Oncogenes 
and Tumor Suppressor Genes”, 2015). Tumor suppressor genes assist in slowing down 
the division of cells and in the control of apoptosis. If mutated, tumor suppressor genes 
no longer function correctly and therefore cannot continue to regulate cell division 
resulting in rapid cell growth and inability to commit cell suicide. It is estimated that 
around 10% of breast cancers are due to hereditary predisposition (Luo, 2001). Breast 
cancer has been linked to the inheritance of two tumor suppressor genes, BRCA 1 located 
on chromosome 17 and BRCA 2 located on chromosome 13 (Luo, 2001). Although not 
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specifically inherited, a woman’s chance of developing breast cancer increases if there is 
a family history of the disease in close relatives such as the mother, grandmother or sister 
(“Breast Cancer Risk in American Women”, 2012). Also, having a male relative with a 
history of breast cancer can increase one’s chances of development (“Breast Cancer Risk 
in American Women”, 2012). Other risk factors include heavy alcohol consumption, 
obesity and being physically inactive. Out of all ethnic groups, breast cancer is diagnosed 
more often in white women compared to African Americans, Hispanics, or Native 
Americans.  
BREAST CANCER STAGING 
When caught early, most forms of breast cancer are considered potentially 
curable. Because of this, regularly scheduled mammograms have become increasingly 
important for women. Mammography has been shown to increase the survival rate of 
breast cancer patients. However, not all women receive adequate screening. In a 1992 
study of 8,805 women aged 50 to 74 years old only 47% of the women received a 
mammogram. Of this 47% there were increased mammography rates of between 3%-5% 
were observed for white, married, women in the higher estimated household income 
group (McCarthy, 2018). Education and stressing the importance of regularly scheduled 
mammograms is crucial to decrease the mortality rate of breast cancer. Through 
mammograms, breast cancer lumps can be detected before symptoms have developed 
(“Breast cancer Statistics and Resources”, 2019) Through the screening, if a mass is 
discovered it will either be categorized as benign or malignant. If the mass is benign, 
simple procedures can be conducted in order to remove the mass, if the patient so desires. 
On the other hand, if the mass is predicted to be cancerous, a biopsy is necessary to 
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determine the exact stage of cancer the mass is which is vital to an effective treatment 
plan. Breast biopsies are procedures which involve removing a small part of the breast 
lump in order for further testing (“Breast Biopsy”, 2019). While the specific procedure 
can vary depending on the size of the lump or its position, usually a small needle is 
placed in the lump and cells and fluid are extracted. In some cases, a surgical biopsy may 
be necessary in order to remove the entire mass for a more in-depth tissue analysis. To 
determine if breast cancer has become invasive, often doctors will biopsy the underarm 
lymph nodes, as this is the first-place breast cancer tends to spread (“Breast Cancer 
Stages: 0 Through IV”, 2019). Test results can reveal if the mass is cancerous or not as 
well as the stage of the cancer (“Breast Biopsy”, 2019). There are several hormonal 
markers that are used for breast tumor subtyping. These include the status of estrogen 
receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) 
(Dai, 2016). Testing of these markers are routine in breast cancer pathology. These 
hormonal and growth receptors are important in cell growth mediation. If a tumor is ER 
or PR positive, the cancer cells may receive signals from estrogen or progesterone that 
promote growth (Dai, 2016). The proto-oncogene protein, HER2, promotes the growth of 
cancer cells. Protein expression is commonly amplified in cancer cells. Protein 
expression can be assayed by immunohistochemistry technique (IHC). Treatments that 
can target HER2 proteins are typically very successful if the tumor is HER2 positive.  
Through detection and biopsy, the stage and type of cancer can be determined. 
There are two very different types of breast cancer. In situ cancer is used to describe 
cancer that is noninvasive and stays within the milk ducts or lobules in the breast. On the 
other hand, more than 80% of breast cancers are invasive and infiltrate surrounding or 
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distant tissues through breaking through breast glands and ducts (“Breast Cancer 
Statistics and Resources”, 2019). 
 
Figure 2: In Situ Non-Invasive Cells  vs. Invasive Cells. This image compares the cells in 
a tumor. With noninvasive cells, the tumor is compact. With the invasive tumor, cells 
have begun to leave the cellular environment and at this point can spread to other parts of 
the body. Figure constructed by author.  
 
The stage of cancer shows how much the tumor has progressed or if it has spread 
to neighboring tissues. Breast cancer is staged on a number scale from 0 to IV with 0 
being noninvasive cancer and IV being metastatic cancer (“Breast Cancer Stages: 0 
Through IV”, 2019). The Tumor, Node, Metastasis (TNM) system is a specific staging 
system defined by the American Joint Committee on Cancer that classifies stages so there 
can be a uniform discussion of the disease for all physicians (“Breast Cancer Stages: 0 
Through IV”, 2019). The system is as follows, T: the size of the cancer tumor and 
whether or not it has grown into nearby tissues, N: whether the cancer is in the lymph 
nodes, and M: whether the cancer has spread to other parts of the body beyond the breast 
(“Breast Cancer Stages: 0 Through IV”, 2019). There are further staging guidelines to 
determine the extent of breast cancer. Stage 0 describes noninvasive breast cancers where 
the abnormal cells have not broken out of the breast. Stage I is used to describe breast 
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cancer that has spread into neighboring tissues. This stage is broken into two 
subcategories IA and IB. Stage IA is the case where the breast cancer is only two 
centimeters and the lymph nodes have not been invaded. IB is the diagnosis when there 
are no cancer cells in the actual breast but rather small groups of cancer cells no larger 
than two millimeters are found in the lymph nodes or maximum two-centimeter mass 
along with small groups of cancer cells in the lymph nodes. Stage II breast cancer also 
has two subcategories. Stage IIA is used to describe breast cancer in which the cancer in 
the lymph nodes is larger than two millimeters or the tumor is larger than two centimeters 
but smaller than five centimeters. Stage IIB is the situation in which the tumor is between 
two and five centimeters and there are small groups of cells in the lymph nodes or if the 
tumor is larger than five centimeters, but the cells have not spread to axillary lymph 
nodes. Stage III has three subcategories; IIIA, IIIB, and IIIC. Stage IIIA is when the 
tumor is larger than five centimeters and small groups of cells are found in the lymph 
nodes. Stage IIIB describes a situation in which the tumor may be any size, but it has 
spread to the chest wall and or skin of the breast. Stage IIIC describes breast cancer that 
has either invaded to ten or more axillary lymph nodes or has spread above the axillary 
lymph nodes and moved into the collarbone. Stage IV is used to describe breast cancer 
that has spread beyond the breast or axillary lymph nodes and has invaded tissues such as 
lung, bone, skin, liver or brain (“Breast Cancer Stages: 0 Through IV”, 2019). The actual 
process of metastasis is still considered to be somewhat enigmatic; however, studies have 
shown that there are preferential organs and tissues that breast cancer may spread to 
(Chen, 2018). This non-random preferential metastasis is known as organotrophic 
metastasis. Tumor cells have the ability to interact with the extra cellular matrix to 
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facilitate metastasis and initiate growth. Invasive breast cancers can be categorized into to 
subcategories; invasive ductal carcinomas (IDC) or invasive lobular carcinomas (ILC) 
(Chen, 2018). The IDC preferentially metastasize to lungs, distant lymph nodes, and the 
central nervous system. Meanwhile, ILC has three times the frequency of metastasis into 
the peritoneum, gastrointestinal tract, and ovaries (Chen, 2018). By identifying the 
particular stage the breast cancer is in, an accurate treatment plan can be established for 
the patient.  
Depending on the Stage and type of breast cancer, the treatment plan can differ. 
There are several types of cancer treatments including chemotherapy, surgery, radiation, 
and hormone therapy. In some cases, oncologists will opt to use a combination of these 
treatments in order to best fight the cancer. If possible, surgery will be performed initially 
to remove tumor masses. Mastectomies are commonly performed to remove breast 
cancer. There are varying mastectomy surgeries that vary in levels of invasiveness. Total 
mastectomies (TM) are the removal of the total breast, overlying skin and nipple (Shah, 
2014). Skin-sparing mastectomies (SSM) which conserve as much skin as possible. 
Modified radical mastectomies (MRM) involve complete removal of the breast as well as 
a large portion of the pectoral muscles and axillary lymph node dissection. There are also 
prophylactic mastectomies (PM) in which a patient may opt for to lower their chances of 
a breast cancer diagnosis if they are positive for the breast cancer genes BRCA1 and 
BRCA2. Postsurgical treatments may be used if the entire tumor is not removed. While 
chemotherapy treatments may differ, they all attack quickly dividing cells in the human 
body. Chemotherapy is often used as a neoadjuvant therapy before surgical removal to 
decrease the size of the tumor. Chemotherapy treatment can cause many deleterious side 
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effects for patients due to the cytotoxicity of the chemicals used. Radiation, at a high 
energy levels, aims to destroy cells’ DNA resulting in cell cycle arrest for cancer cells. If 
the cancer is hormone-receptor-positive, hormonal therapies can be used to block or 
lower the levels of hormones in the body that will ultimately halt cancer progression. If 
the cancer is hormone-receptor-negative, it will be unreceptive to hormonal therapy. All 
of these treatment options can increase the overall survival for patients, but it is important 
to continue to research new methods that may be more beneficial and less toxic to the 
patients.  
IMPORTANCE OF RESEARCH 
Researching and finding a cure for cancer brings hope to those struggling with the 
disease or those who are survivors and already fought the battle. Advances in medicine 
have provided new options for treating breast cancer, decreased the mortality rate, and 
increased the survival rate. Through additional research, both the quality of life and 
quantity of life saved can be improved for patients. However, the fear of cancer does not 
end once a patient is declared in remission. There are future concerns of recurrence, 
fertility issues, or the genetic effect on future offspring (Leigh, 2000). Survivors yearning 
to feel empowered by their battle have politically pushed for an increase in government 
funded cancer research hoping to eventually decrease the cost of treatment (Leigh, 2000). 
Financial burden should not be a patient’s major concern while they are fighting for their 
lives. Continued research of the most effective treatment plans can have positive effects 
on the price tag behind being diagnosed with cancer. Increasing patient access to clinical 
trials and education regarding early detection can further improve cancer prevention 
methods and quality of care if diagnosed. 
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NATURAL PRODUCTS 
There are several products in nature that can be researched in order to determine 
their potential for treating cancer. In particular, ascorbic acid (Vitamin C) and alpha 
tocopherol (Vitamin E) have been studied to understand their antioxidant effects on 
cancer. Vitamin C and Vitamin E can both be found in a variety of natural food sources. 
Vitamin C is found in many leafy greens like broccoli and kale as well as citrus fruits like 
kiwi and oranges. Vitamin E is most commonly found in vegetable oils such as sunflower 
seed oils or nuts, like peanuts and almonds.  
Vitamin C is an essential cofactor for α-ketoglutarate-dependent dioxygenases. 
Examples are prolyl hydroxylases, which play a role in the biosynthesis of collagen and 
in the down-regulation of hypoxia-inducible factor (HIF)-1, a transcription factor that 
regulates many genes responsible for tumor growth, energy metabolism, and neutrophil 
function and apoptosis (Traber, 2011). Vitamin C-dependent inhibition of the HIF 
pathway may provide alternative or additional approaches for controlling tumor 
progression, infections and inflammation. Vitamin E functions as an essential lipid 
soluble antioxidant, scavenging hydroperoxyl radicals in lipid milieu (Traber, 2011). 
Human symptoms of vitamin E deficiency suggest that its antioxidant properties play a 
major role in protecting erythrocyte membranes and nervous tissues. As an antioxidant, 
vitamin C provides protection against oxidative stress-induced cellular damage by 
scavenging reactive oxygen species, vitamin E-dependent neutralization of lipid 
hydroperoxyl radicals, and by protecting proteins from alkylation by electrophilic lipid 




Figure 3: Vitamin E Molecular Structure.  
 
   Figure 4: Vitamin C Molecular Structure.  
 
CANCER AND MITOCHONDAL RESPIRATION 
All cells undergo oxidative phosphorylation in the mitochondrial matrix if there is 
oxygen present. Respiration is a series of reactions in which electrons are passed on 
through the mitochondrial electron transport chain with oxygen serving as the final 
electron acceptor. Once oxygen is reduced to water, the process can begin again. 
Respiration and the reduction and oxidation of electron carriers allows for adenosine 
triphosphate (ATP) production which is our source of energy in the body. Mitochondrial 
metabolism is a tightly regulated process.  
This tightly regulated system can become leaky and oxygen can be partially 
reduced to a superoxide anion (O2
-) (Hoeks, 1970). The mitochondrial leak typically 
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occurs in complexes I and III of the electron transport chain (Nita, 2016). However, there 
are multiple pathways in which ROS production can be stimulated. Antioxidants, found 
in many foods and other natural products, are used in order to avoid the formation of 
oxide radicals because these radicals can harm and age cells via oxidative damage. 
Reactive oxygen species (ROS) are used to describe a variety of molecules and free 
radicals (Hoeks, 1970). Oxygen, the eighth element of the periodic table, is a colorless 
gas at room temperature with two unpaired electrons in its outer shell. Because both of 
these electrons have the same spin in the ground state, oxygen is not typically a reactive 
species (Hoeks, 1970). However, when partially reduced by one electron at a time, the 
superoxide radical becomes the precursor for many ROS (Hoeks, 1970). This precursor 
can be converted to hydrogen peroxide (H2O2) and then further broken down to water 
(H2O). Low levels of ROS production are required for physiological functions such as 
normal cell proliferation, signal transduction, and gene expression (Nita, 2016).  
Hydrogen peroxide (H2O2) is an important secondary chemical messenger in cellular 
signaling (Liou, 2010). At lower levels, hydrogen peroxide can stimulate cell 
proliferation in cancer cells and also upregulates messenger ribonucleic acid (mRNA) 
levels of cyclins that participate in the cell cycle (Liou, 2010). Oxidative stress is any 
state where there is an excessive level of ROS and an imbalance of antioxidants. High 
ROS levels can damage cellular proteins, lipids and DNA leading to disruptions in cells 
that can contribute to carcinogenesis (Liou, 2010).   
Under normal conditions, there are several pathways in the body that are designed 
to detoxify cells from high levels of ROS to avoid oxidative damage. Glutathione (GSH) 
is an antioxidant that protects cells from oxidative stress. In this system, disulfide bonds 
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(S-S) are reduced to thiol group (SH). Glutathione is oxidized to glutathione disulfide 
(GSSG) which allows for the breakdown of hydrogen peroxide (H2O2) to water (H2O) 
and GSSG is reduced to refill the GSH pool to combine with another cysteine when 
another reaction needs to take place (Liou, 2010). This system can control the oxidative 
equilibrium in cells. Elevated rates of reactive oxygen species (ROS) have been detected 
in almost all cancers, where they promote many aspects of tumor development and 
progression. However, tumor cells also express increased levels of antioxidant proteins to 
detoxify from ROS, suggesting that there is a delicate balance of intracellular ROS levels 
that is required for cancer cell function (Liou, 2010). If ROS levels remain at high levels, 
DNA will be further damaged, and cells will go into a series of apoptosis cascades. If 
antioxidant levels are too high, ROS levels will decrease, and the tumor will progress and 
grow even more. This conundrum shows the balance of ROS and antioxidants in cancer 
cells. Treatments can focus on tipping the balance to ROS-induced apoptosis signaling in 
cancer cells which will decrease tumor progression.  
Apoptosis is a vital process that maintains the integrity of cells. It is a tightly 
regulated process but with an increase in intracellular ROS, cell cycle arrest and 
apoptosis may be induced (Liou, 2010). ROS, such as H2O2 and superoxide radical (O2
-) 
can trigger the release of cytochrome c from the mitochondria which begins an apoptosis 
cascade (Redza-Dutordoir, 2016). Mitochondrial release of H2O2 can lead to the 
activation of c-Jun N-terminal kinases (JNKs) (Liou, 2010). In the presence of increased 
mitochondrial ROS levels, JNKs catalyze the phosphorylation and downregulation of 
anti-apoptotic proteins such as B-cell lymphoma 2 (BCL-2) (Liou, 2010). BCL-2 has 
been seen to inhibit apoptosis by blocking the oligomerization of BAX/BAK. This 
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oligomerization leads to the release of apoptotic signals from the mitochondria. If BCL-2 
is downregulated, BAX/BAK can bind stimulating apoptotic cascades (Tzifi, 2011). 
Progression through this pathway releases cytochrome c that triggers a further apoptosis 
cascade. High levels of ROS can induce the expression of the p53 gene. This gene plays a 
crucial role in regulating apoptotic signals, such as targeting the upregulation of BAX and 
BAK, that will lead the cell into the intrinsic pathway and ultimately cell death (Redza-
Dutordoir, 2016). Members of the mitogen activated pathway kinase (MAPK) have also 
been implicated in apoptotic signaling in response to increased ROS generation. The 
MAPK pathway is composed of a series of serine/threonine specific protein kinases that 
controls genes transcription, cell growth, and apoptosis. This pathway is activated via a 
phosphorylation change between specific serine and threonine residues on target proteins 
(Hellmich, 2007).   
Antioxidants, like Vitamin E and Vitamin C, have been shown to inhibit tumor 
cell proliferation (Liou, 2010). Important in the relation of anticarcinogen and pro-
oxidative action is that high concentrations of Vitamin C has been shown to induce cell 
death and apoptosis in various tumor cell lines (Rietjens,2002). At higher concentrations, 
it acts as a pro-oxidant by inducing ROS (Chakraborthy, 2014). Whether Vitamin C has a 
net pro-oxidant or antioxidant effect depends on the concentration gradient and redox 
state of a cell (Chakraborthy, 2014). Vitamin E is less consistent with its pro-oxidant 
activities. Several other studies have reported Vitamin E to be a tumor initiating and 
tumor promoting carcinogen and does not demonstrate cancer preventative effects (Yang, 
2013). High levels of antioxidants can begin to detoxify the ROS in cells leading to 
further proliferation of the tumor. At these higher levels, tumors may become well-
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adapted to the oxidative stress and develop enhanced, endogenous antioxidant capacity 
(Liu, 2018). At certain levels, particularly low doses, ROS can actually stimulate cell 
proliferation in cancer cells (Liou, 2010). Angiogenesis, EMT, and cell cycle progression 
can all be induced by low ROS levels. Because of this activation, it is important to 
carefully manage the ROS levels in cells.  
Hypoxia and oxygen levels have also been studied to show the importance in 
cancer cells. Limitations in oxygen for a prolonged period can lead to tumor cell death 
(Liou, 2010). However, tumor cells are capable of switching metabolic states to adapt to 
low oxygen levels. This is known as the Warburg effect. This is a shift from aerobic 
metabolism to anaerobic glycolysis. In poor oxygenated states, there is an increase in 
HIF-1 expression which can contribute to cancer cell invasiveness. Elevated expression 
and activation of HIF-1 protein can stimulate the production of the angiogenic growth 
factor, VEGF, that recruits new blood vessels which provide further nutrients for the 
tumor. 
MATERIALS AND METHODS 
 Cell Culture/ Compound Treatment 
Human breast tumor MCF-7 and MDA-MB-231 cells were obtained from the 
American Type Culture Collection. The bone metastatic MDA-MB- 231 derived BOM-
1883 and MCF-7-derived MCF-7 BOM subclones were originally isolated by Dr. J. 
Massagué’s group at Memorial Sloan Kettering Cancer Center, New York City, New 
York and obtained from Dr. Kounosuke Watabe at Wake Forest University Baptist 
Medical Center, Winston-Salem, North Carolina.   
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The MCF-7 is a cell lined was established by Dr. Soule in 1973 at Michigan 
Cancer Foundation. These cells are derived from a 69-year old woman with metastatic 
breast cancer (Comşa, 2015). Breast MCF-7 cells are estrogen receptor (ER)-positive and 
progesterone receptor (PR)-positive (Comşa, 2015). The MDA-MB-231 cell line is 
derived from a patient with invasive ductal carcinoma. The cell line is ER, PR, and 
epithelial-cadherin negative (Welsh, 2013). The MDA-MB-231 cells also do not 
overexpress the HER2 growth factor receptor, so they serve as an excellent model for 
triple-negative breast cancer (Welsh, 2013). The BOM-1883 line was derived from 
MDA-MB-231 parental cell line and is a bone metastasis–prone subline (Y. Kang, K. 
Pantel, Cancer Cell 23, 573-581 (2013)). The MCF-7 BOM line is also a bone 
metastasis–prone subclone, derived from the MCF-7 parental cell line (Cancer Research, 
2013, DOI: 10.1158/0008-5472.CAN-12-2037). All cell lines were maintained in RPMI-
1640 Medium with L-glutamine 2 mM (HyClone, SH30027.02) supplemented with fetal 
bovine serum [FBS, 10% (v/v)] (Hyclone, 30910.03), penicillin (100 units/mL) and 
streptomycin (100 μg/mL) (ThermoFisher Scientific, 15140163).  
Sulforhodamine B (SRB) Viability Assay  
The SRB viability assay was performed to determine cell viability in 96-well 
plate-based format. SRB assays are used to investigate cytotoxicity in cell-based studies 
(Orellana, 2016). Exponentially grown cells maintained in 10 cm plates (Nunc) were 
trypsinized with 1 mL 0.25% Trypsin (Gibco, 2520056). They were then collected with 
10 mL of 10% fetal bovine serum (FBS) RPMI1640 media. The cells were then further 
diluted with 10% FBS. A hemocytometer was used to count and determine cell density. 
For the cell seeding procedure, cells were added in a volume of 100 μL per well into 96-
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well plates (Thermo Scientific-167542) at the specified densities of MCF 7: 30000 
cells/well, MDA-MB-231: 20000 cell/well, BOM-1883: 15000 cells/well, and MCF-7 
BOM: 15000 cells/well. For compound treatments of alpha-tocopherol (Vitamin E) 
(Sigma-Aldrich T3251) and ascorbic acid (Vitamin C) (ACRO-40147100), working 
dilutions prepared at 2x final concentrations in serum-free RPMI1640 media with 
penicillin and streptomycin were added to the 96-well plates in a volume of 100 μL per 
well. Vitamin E was dissolved in dimethyl sulfoxide (DMSO) (Sigma Aldrich-D2438) 
and Vitamin C was dissolved in deionized distilled water. Two 96-well plates were 
seeded for each experimental treatment to observe the effects a hypoxic environment has 
on cell viability. For the normoxic environment, plates were placed in a humidified 
atmosphere (5% CO2 and 95% air) at 37 °C. Cells exposed to the hypoxic environment 
were placed in a chamber with a humidified environment of 1% O2/5% CO2/94% N2. The 
four total plates incubated for 48 hours in their respective environments. Once the 
incubation was complete, 100 μL of media was removed from each well. The fixation 
process of the cells consisted of the addition of 100 μL of 20% trichloroacetic acid (TCA) 
(Sigma-T9-159-250G) in 1x Phosphate Buffered Saline (PBS) (Fisher, BP399-1), 
followed by incubation at 4°C for one hour. The plates were washed with tap water four 
times before being placed in the hood to dry. The next day, 70 μL/well of 0.4% 
Sulforhodamine B (SRB) (MP, 194599) in 1% acetic acid (Fisher Scientific-A38S-500) 
was added to the 96 well plates in order to stain the fixed cells. After 10 minutes, the 
plates were washed with 1% acetic acid (Fisher Scientific-A38S-500) three times. The 
plates were then inverted and laid in the hood to dry. The following day, 100 μL of 10 
mM Tris base (Fisher Scientific, BP152-1) was added to each well and every plate was 
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shaken for three minutes. The plates were then analyzed using the SpectaFluor plate and 
Magellan software at an absorbance range of 492-620 nm. The difference in absorbance 
between 492 and 620 nm is used to calculate cell viability. The extent of OD values 
correlate with the number of viable cells. From the data collected, results were interpreted 
via Prism 8 software. Cell viability data are presented as ‘% Inhibition’ or ‘% Control’ as 
specified, calculated using the formula: 
 % Inhibition = [1 – (ODcompound/ODcontrol)] × 100 
 % Control = ODcompound/ODnormoxic control × 100 
The dilutions for the both compounds can be found below. The concentrations applied to 
each well in the 96-well plates can be found below as well.  
 
Table 1: Vitamin C Dilutions 
Vitamin C Dilutions 
(Final 
concentrations) 
Stock Dilution Media Volume 
300 μM  50.4 μL of 50 mM  4.15 mL  
100 μM  1.1 mL of 300 μM 2.2 mL  
30 μM 330 μL of 300 μM 2.970 mL  
10 μM  330 μL of 100 μM 2.970 mL 





Table 2: Vitamin E Dilutions  
Vitamin E Dilutions Stock Dilution Media Volume 
300 μM  50.4 μL of 50 mM  4.15 mL  
100 μM  1.1 mL of 300 μM 2.2 mL  
30 μM 330 μL of 300 μM 2.970 mL  
10 μM  330 μL of 100 μM 2970 μL 
1 μM 300 μL of 10 μM 2700 μL 
 
 
Table 3: Vitamin C Concentrations in a 96-Well Plate   
 MCF 7 BOM-1883 MD-MBA-231 MCF-7-BOM 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B             
C             
D             
E             
F             
G             
H             
 
Media Control 100 μL (negative control) 
Media Control 100 μL (negative control) 
1 μM Vitamin C 
10 μM Vitamin C 
30 μM Vitamin C 
100 μM Vitamin C 
300 μM Vitamin C 
10 μM Cycloheximide (positive control)  
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Table 4: Vitamin E Concentrations in a 96-Well Plate  
 MCF 7 BOM-1883 MD-MBA-231 MCF-7-BOM 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B             
C             
D             
E             
F             
G             
H             
 
RESULTS 
 The results below show the percent inhibition curves for the different cell lines 
under normoxic and hypoxic conditions. The IC50 values can be found in the graphs 
below. IC50 values represent the concentration of the test compound that results in 50% 
inhibition. This is a measure of the effectiveness of a chemical suppressing a specific 
biological function, in this case the proliferation/viability of tumor cells. This 
measurement shows how much of a compound is needed to inhibit a process by half. 
From these graphs, the IC50 value can be obtained from the linear regression graph 
analysis. The IC50 values for the two different compounds can be found in Table 5. 
Figure 5 and Figure 6.  
Media Control 100 μL (negative control) 
Media Control 100 μL (negative control) 
1 μM Vitamin E 
10 μM Vitamin E 
30 μM Vitamin E 
100 μM Vitamin E 
300 μM Vitamin E 
10 μM Cycloheximide (positive control)  
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 Figure 5A     Figure 5B 
 
  
Figure 5C        Figure 5D 
 
 Figure 5E     Figure 5F 
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Figure 5G    Figure 5H 
Figure 5A-H: Inhibition Tumor Cell Proliferation by Vitamin C after 48 hours at 
various Concentrations  
 
 
Figure 6A     Figure 6B 
 
Figure 6C     Figure 6D 
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 26 
Figure 6E     Figure 6F 
 
Figure 6G     Figure 6H 
Figure 6A-H: Inhibition of Tumor Cell Proliferation by Vitamin E after 48 hours  
at Various Concentrations 
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Figure 7A      Figure 7B 
 
Figure 7C      Figure 7D 
N=12 
Figure 7A-D: Cell Proliferation/Viability after 48 hours under normoxic and hypoxic 





























































Table 5: Vitamin C IC50 Values  
Cell line IC50 Value (M) 
MCF-7 Normoxia 216 
MCF-7 Hypoxia 15.7 
BOM-1883 Normoxia 319 
BOM-1883 Hypoxia 256 
MDA-MB-231 Normoxia 869 
MDA-MB-231 Hypoxia  6.008e+024 
MCF-7-BOM Normoxia  608520 
MCF-7-BOM Hypoxia 226 
 
Table 6: Vitamin E Tumor Cell Growth IC50 Values 
Cell line IC50 Value (M) 
MCF-7 Normoxia 12460 
 
MCF-7 Hypoxia 6.577e-033 
 
BOM-1883 Normoxia 27255 
BOM-1883 Hypoxia 105192 
MDA-MB-231 Normoxia 52960 
 
MDA-MB-231 Hypoxia  1.819e+095 
 
MCF-7-BOM Normoxia  4523 
 





It was expected that as the concentration of vitamin C and vitamin E increased in 
the cells, more ROS would be generated and there would be a decrease in cell viability 
due to ROS induced apoptosis. The MCF-7 cell line under both the normoxic and 
hypoxic environment showed the greatest response to vitamin C. At a vitamin C 
concentration of 300 μM, there was an average of 68% inhibition for the MCF-7 
Normoxic condition with an IC50 value of 216 M. With a small IC50 value, the drug is 
considered to be more effective because it takes less of the compound to reach 50% 
inhibition. The MCF-7 cells in a hypoxic environment showed similar results with a 
particularly low IC50 value of 15.7 M. These results can be viewed in Figures 4A and 
4B. The remaining cell lines did not show profound results with varying concentrations 
of vitamin C. This could be attributed to the fact that because MCF-7 is ER and PR 
positive, the cell line can interact differently with the vitamins. When comparing to the 
effects of vitamin C, vitamin E was less effective, as the vitamin E treatment did not 
significantly affect the cell lines. This result can be visualized in Figure 5. There is little 
research to show the effectiveness of Vitamin E as a pro-oxidant. However, there is 
substantial evidence that vitamin E can promote tumor proliferation, instead of promoting 
apoptosis. At certain concentrations of Vitamin E, you can see enhanced tumor activity. 
There are studies that show that vitamin E has a biphasic effect which is stimulatory at 1 
and 10 μM and inhibitory at 100 μM (ElAttar, 1992). This is an interesting finding and 
can be used to explain why Vitamin E has varying capabilities at different concentrations. 
The error in these results can be attributed to human error in improper cell seeding 
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procedure. To improve the results, this experiment could be carried out multiple times 
with more careful attention to the seeding of cells into the 96-well plates. Because 
Vitamin E is not soluble, there could also be error in dilutions of this compound.  
To further determine the effects of vitamin C and vitamin E, additional research 
should be continued in order to measure the production of ROS by both of these 
compounds. If it is found that there is negligible ROS production from vitamin C and 
vitamin E, the experiment could be repeated with other pro-oxidants. Levels of ROS 
production can be measured for fluorescent assays that measure DNA and RNA damage 
as well as lipid peroxidation.  
Figures 6 shows the results of tumor cell proliferation/viability under a hypoxic or 
normoxic environment. The protein synthesis inhibitor cycloheximide was used as 
positive control in this part of the experiment to suppress all cancer cells. Relative to 
normoxia, the hypoxic environment decreased cell proliferation and viability. This is an 
intriguing result, because there are situations in which a hypoxic environment can 
upregulate the transcription of VEGF, resulting in the recruitment of new blood vessels to 
the tumor for sustained proliferation.  It is possible that in the absence of endothelial cells 
to form new blood vessels, the increase in secreted VEGF protein levels does not 
contribute to improved cell proliferation/survival.  
To better understand the effects of ROS-induced apoptosis in cancer cells, there 
could be a more in depth look into the depletion of the glutathione redox system. As 
previously stated, glutathione is an important regulator in controlling the redox 
environment of a cell. This system is responsible for ridding the cell of harmful ROS. If 
the glutathione redox system was blocked or inhibited, ROS levels could possibility 
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increase. The effect of this ROS increase has on cell viability could prove beneficial for 
future therapeutic treatments.  
 
CONCLUSION 
 In reflection, there are multiple pathways that can be targeted to reduce tumor 
proliferation and promote apoptosis. Our hypothesis was that antioxidants, vitamin C and 
vitamin E, have pro-oxidant capabilities. These compounds would be able to stimulate 
ROS production which can lead to an oxidative stress environment in the cancer cell. 
There have been several studies that have shown that at higher levels of ROS, apoptosis 
can be induced through a variety of signaling cascades. The results from these 
experiments is the deduction that vitamin C does have pro-oxidant activity in tumor cells. 
This compound proved more effective on inhibiting tumor cells. The results were most 
visible in the MCF-7 cell line. The results from vitamin E were inconclusive compared to 
the results for vitamin C. Furthermore, the effect of a hypoxic environment decreased cell 
proliferation in the experiments. Although the two compounds did not produce a 
significant antitumor effect, these two ideas shed light into new ways that cancer can be 
targeted. Further investigation of oxidative stress and the production of ROS in cancer 
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